|
Match
|
Document |
Document Title |
|
|
7575762 |
Composition comprises sustained-release fine particles and manufacturing method thereof
The present invention relates to a composition comprising sustained-release fine particles, characterized in that it contains sustained-release fine particles that can be used in...
|
|
|
7550158 |
Controlled release by extrusion of solid amorphous dispersions of drugs
Controlled release dosage forms for low solubility drugs are disclosed wherein an amorphous solid dispersion of the drug is coated with a non-dissolving and non-eroding coating that controls the...
|
|
|
7524515 |
Pharmaceutical safety dosage forms
Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant...
|
|
|
7514100 |
Controlled release hydrocodone formulations
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
|
|
|
7488498 |
Antidiabetic preparation for oral administration
There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a...
|
|
|
7456150 |
Pulmonary delivery of active fragments of parathyroid hormone
Systemic delivery of parathyroid hormone to a mammalian host is accomplished by inhalation through the mouth of a dispersion of an N-terminal fragment of PTH. It has been found that such...
|
|
|
7455864 |
Melatonin-based composition for improved sleep
A method for improving sleep in an individual comprising the administration of a composition comprising melatonin, lavender flower extract and Ferula extract is provided. The composition may be...
|
|
|
7442387 |
Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene...
|
|
|
7438930 |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration...
|
|
|
7431943 |
Controlled release and taste masking oral pharmaceutical compositions
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic,...
|
|
|
7427413 |
Stable shaped particles of crystalline organic compounds
The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred...
|
|
|
7422758 |
Sustained release vitamin composition
A therapeutic formulation in the form of a beadlet, suitable for oral administration and adapted to provide immediate and sustained release of therapeutic material. Each beadlet comprises an...
|
|
|
7419686 |
Opioid agonist/antagonist combinations
The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid...
|
|
|
7413750 |
Process for producing solid oral dosage forms with sustained release of active ingredient
The present invention relates to a process for producing solid oral dosage forms with sustained release of active ingredient, comprising at least one active ingredient, a preformulated mixture of...
|
|
|
7387791 |
Liposome drug delivery
This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used...
|
|
|
7384653 |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second...
|
|
|
7335380 |
Amlodipine free base
Amlodipine free base can be formulated into a convenient oral dosage form, especially a tablet, without excessive stickiness or tablet punch residue. The amlodipine free base can be crystalline...
|
|
|
7320802 |
Methods of treatment using nanoparticulate fenofibrate compositions
The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective...
|
|
|
7314640 |
Formulation and process for drug loaded cores
The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core.
|
|
|
7303765 |
Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same
L-carnitine which has a particle size such that it substantially passes through a 100 USBS mesh sieve exhibits an increased bioavailability, a decreased hygroscopicity, and may be conveniently...
|
|
|
7276252 |
Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form
A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings,...
|
|
|
7276249 |
Nanoparticulate fibrate formulations
The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective...
|
|
|
7273624 |
Stable dosage forms containing ubiquinones
The invention relates to stable solid dosage forms for peroral administration containing, in addition to an ubiquinone, at least one thermoplastically processible matrix-forming auxiliary agent.
|
|
|
7258872 |
Chromone enteric release formulation
Orally administered chromones have been found to be effective in the treatment of allergic conditions such as asthma, general food allergies, ulcerative colitis, atopic eczema, chronic urticaria,...
|
|
|
7255876 |
Composition comprises sustained-release fine particles and manufacturing method thereof
The present invention relates to a composition comprising sustained-release fine particles, characterized in that it contains sustained-release fine particles that can be used in...
|
|
|
7238372 |
Methods for inhibiting tumor cell proliferation
The subject invention concerns methods for inhibition of STAT biological functions using platinum complexes.
|
|
|
7229644 |
Pharmaceutical formulations of modafinil
The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their...
|
|
|
7229642 |
Amino acid modulated extended release dosage form
Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an...
|
|
|
7217429 |
Tableted oral pharmaceutical dosage form, with enteric coating, containing a compound of benzimidazole labile in an acid medium
The pharmaceutical dosage form consists of a plurality of units containing a benzimidazole compound labile in an acid medium as the active principle, each unit being comprised of an inert core, a...
|
|
|
7192608 |
Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules
The present invention provides coated granules using drug granules containing a water soluble drug as an active ingredient at a high density, which is superior in uniform content and stability, and...
|
|
|
7189415 |
Rapidly disintegrable pharmaceutical composition
The present invention relates to a pharmaceutical composition useful for rapid disintegration, which comprises a sparingly soluble medicament held on a gel-forming water-soluble polymer as a solid...
|
|
|
7175854 |
Pharmaceutical preparation comprising an active dispersed on a matrix
The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a...
|
|
|
7166301 |
Immediate release medicinal compositions for oral use
The present invention relates to an immediate release oral pharmaceutical composition which comprises as an active ingredient calcium salt of a benzylsuccinic acid derivative represented by the...
|
|
|
7163696 |
Pharmaceutical formulations
The invention provides a controlled-release pharmaceutical formulation for oral administration comprising...
|
|
|
7160559 |
Controlled release galantamine composition
The present invention is concerned with controlled release compositions for oral administration comprising galantamine; and with processes of preparing such controlled release compositions.
|
|
|
7157103 |
Pharmaceutical formulation containing irritant
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating...
|
|
|
7157095 |
Multiple-delayed release antifungal product, use and formulation thereof
An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the C max for the anti-fungal product being reached in less...
|
|
|
7153840 |
Aqueous fludarabine phosphate composition
This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which...
|
|
|
7148207 |
Oral fludara of high-purity formulation with quick release of active ingredient
This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
|
|
|
7144587 |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and a bittering agent in an effective amount to...
|
|
|
7141250 |
Pharmaceutical formulation containing bittering agent
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of a bittering agent to impart a bitter...
|
|
|
7138138 |
Pharmaceutical formulation having a masked taste and method for the production thereof
The invention relates to a pharmaceutical formulation in the form of a powder which is administered orally in an aqueous suspension, having a masked taste, and comprising at least one cellulose...
|
|
|
7125562 |
Rapidly disintegrating methylcellulose tablets
The present invention relates to a rapidly disintegrating tablet for oral administration. The tablet has a first phase and a second phase blended with the first phase. The first phase has a...
|
|
|
7118763 |
Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than...
|
|
|
7115281 |
Processes for the preparation of oral dosage formulations of modafinil
The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles...
|
|
|
7108866 |
Chronotherapeutic diltiazem formulations and the administration thereof
A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing...
|
|
|
7108865 |
Controlled-release dosage forms of azithromycin
A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising...
|
|
|
7087249 |
Treatment of mucosal membranes
The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and...
|
|
|
7087243 |
Pharmaceutical coating composition and method of use
A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for...
|
|
|
7083808 |
Controlled/modified release oral methylphenidate formulations
The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak...
|